• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Redhill Biopharma Ltd.

    5/27/25 7:00:35 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RDHL alert in real time by email
    6-K 1 zk2533268.htm 6-K


    UNITED STATES   
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 6-K
      
    Report of Foreign Private Issuer
    Pursuant to Rule 13a-16 or 15d-16
    of the Securities Exchange Act of 1934
     
    For the month of May 2025
    Commission File No.:001-35773
     
    REDHILL BIOPHARMA LTD.
    (Translation of registrant’s name into English)
     
    21 Ha'arba'a Street, Tel Aviv, 6473921, Israel
    (Address of principal executive offices)
     
    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  

    Form 20-F ☒        Form 40-F ☐



    At the adjourned Annual General Meeting of Shareholders of RedHill Biopharma Ltd. (the “Company”) held on May 26, 2025, all of the resolutions proposed to the shareholders were duly approved. Below are the proposals adopted:


    1.
    To appoint Kesselman & Kesselman, certified public accountants in Israel and a member of PricewaterhouseCoopers International Limited, as the Company’s auditors for the year 2025 and for an additional period until the next Annual General Meeting;


    2.
    To approve the re-election of Mr. Dror Ben-Asher and Dr. Kenneth Reed to the board of directors of the Company (the “Board of Directors”) for an additional three-year term until the annual general meeting to be held in 2028;


    3.
    To approve a renewal of an amended version of the Company’s compensation policy for a three-year period in accordance with the requirements of the Israeli Companies Law, 5759-1999;


    4.
    To approve the grant of restricted share units (“RSUs”) each with respect to one American Depository Share (each representing 10,000 ordinary shares, par value NIS 0.01 each) to the non-executive directors of the Company;


    5.
    To approve the grant of RSUs to Mr. Dror Ben-Asher, the Company’s Chief Executive Officer and Chairman of the Board of Directors;


    6.
    To approve the grant of RSUs to Mr. Rick D. Scruggs, the Company’s Chief Commercial Officer, and Director; and


    7.
    To approve an increase in the Company’s authorized share capital.

    This Form 6-K is hereby incorporated by reference into the Company’s Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File No. 333-232776), on March 25, 2021 (File No. 333-254692), on May 3, 2021 (File No. 333-255710), on January 11, 2022 (File No. 333-262099), on June 27, 2022 (File No. 333-265845), on June 29, 2023 (File No. 333-273001), on June 20, 2024 (File No. 333-280327) and on March 25, 2025 (File No. 333-286082), and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on March 30, 2021 (File No. 333-254848), on August 4, 2023 (File No. 333-273709), on October 13, 2023 (File No. 333-274957), as amended, and on August 9, 2024 (File No. 333-281417).



    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. 

     
    REDHILL BIOPHARMA LTD.
     
     
    (the “Registrant”)
     
     
     
     
     
    Date: May 27, 2025
    By:
    /s/ Dror Ben-Asher
     
     
    Name:   
    Dror Ben-Asher
     
     
    Title:
    Chief Executive Officer
     


    Get the next $RDHL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RDHL

    DatePrice TargetRatingAnalyst
    9/15/2021$23.00 → $21.00Buy
    HC Wainwright & Co.
    8/31/2021$22.00Overweight
    Cantor Fitzgerald
    More analyst ratings